Amyloid-Beta Immunotherapy for the Prevention and Treatment of Alzheimer Disease: Lessons from Mice, Monkeys, and Humans

Authors:

Abstract
Alzheimer disease (AD), the most common form of dementia, is without an effective cure or preventive treatment. Recently, amyloid-beta protein (A β ) has become a major therapeutic target. Many efforts are underway to either reduce the production of A β or enhance its clearance. In 1999, Schenk and colleagues first showed that active immunization with full-length A β lowered cerebral A β levels in transgenic mice. These findings have been confirmed and extended in various transgenic mouse models of AD using both active and passive A β immunization. Cognitive improvement also has been reported in association with active and passive A β vaccination in AD-like mouse models, even in the absence of significant reductions in cerebral A β loads. In 2004, the authors reported that active immunization with fulllength A β in aged nonhuman primates, Caribbean vervets, reduced cerebral A β levels and gliosis. Proposed mechanisms of A β clearance by immunotherapy include disruption of A β aggregates, A β phagocytosis by microglia, neutralization of A β oligomers at the synapse, and increased efflux of A β from brain to blood. A phase IIa clinical trial was halted in 2002 because of the appearance of meningoencephalitis in ∼6% of the AD patients. Although the exact cause of these adverse events is unknown, the immunogen, full-length A β 1-42, may have been recognized as a self-antigen leading to an autoimmune response in some patients. Limited cognitive stabilization and apparent plaque clearance have been reported in subsets of patients who generated antibody titers. Currently, a passive immunization trial with a recombinant humanized monoclonal A β antibody is underway in humans. In the meantime, the authors are developing novel A β peptide immunogens for active immunization to target A β B cell epitope(s) and avoid A β -specific T-cell reactions in order to generate a safe and effective AD vaccine. The authors remain optimistic about the potential of such a vaccine for the prevention and treatment of AD.

This publication has 1 reference indexed in Scilit: